# US 2025/0059277 A1 · Anti-pd1 antibodies and their use as therapeutics and diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0059277 A1
- Document ID: US20250059277A1
- Status: Published application
- Kind: A1
- Application number: 18/936,922
- Filed: 2024-11-04
- Published: 2025-02-20
- Earliest claimed: 2013-09-13
- Assignees: BeiGene Switzerland GmbH
- Applicants: BeiGene Switzerland GmbH
- Inventors: Kang LI; Tong ZHANG; Jing SONG; Lanlan XU; Qi LIU; Hao PENG
- Web page: https://patentgrep.com/patent/US20250059277A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/53: Hinge
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A fusion protein, designated P3Z, comprising an extracellular domain, a transmembrane domain, and a cytoplasmic domain, wherein:
(a) the extracellular domain and the transmembrane domain comprise an amino acid sequence of human PD-1, and
(b) the cytoplasmic domain comprises an amino acid sequence of human CD3ζ.

### Claim 22 (depends on 21)

The fusion protein of claim 21, wherein the fusion protein comprises an amino acid sequence according to SEQ ID NO: 90.

### Claim 23 (depends on 21)

A nucleic acid encoding the fusion protein of claim 21.

### Claim 24 (depends on 21)

A cell line expressing the fusion protein of claim 21.

### Claim 25 (depends on 24)

The cell line of claim 24, wherein the cell line is a human T cell line.

### Claim 26 (depends on 25)

The cell line of claim 25, wherein the human T cell line is transfected with a nucleic acid encoding the fusion protein.

### Claim 27 (depends on 21)

A method of assaying, screening or selecting for an anti-PD-1 antibody comprising:
(a) providing a material to be assayed, screened or selected against;
(b) screening the material using the fusion protein of claim 21; and
(c) selecting an anti-PD-1 antibody.

### Claim 28 (depends on 27)

The method of claim 27, wherein the material is incubated with a cell line expressing the fusion protein.

### Claim 29 (depends on 27)

The method of claim 27, further comprising culturing the cell line incubated with the anti-PD-1 antibody with a cell line comprising expression of PD-L1 or PD-L2

### Claim 30 (depends on 27)

The method of claim 27, wherein the anti-PD-1 antibody is selected based on measuring a release of IL-2 from the cell line expressing the fusion protein.

### Claim 31 (depends on 30)

The method of claim 30, wherein the selected anti-PD-1 antibody comprises a heavy chain variable region comprising a heavy chain complementary determining region (CDR) I comprising amino acid residues 6-10 of the sequence of SEQ ID NO: 31, a heavy chain CDR2 comprising the sequence of SEQ ID NO: 32, and a heavy chain CDR3 comprising amino acid residues 3-12 of the sequence of SEQ ID NO: 33; and a light chain variable region comprising a light chain CDRI comprising the sequence of SEQ ID NO: 34, a light chain CDR2 comprising the sequence of SEQ ID NO: 35, and a light chain CDR3 comprising the sequence of SEQ ID NO: 36.

### Claim 32 (depends on 27)

The method of claim 27, wherein the selecting step comprises ELISA, FACS, functional assays, or any combination thereof.

### Claim 33 (depends on 30)

The method of claim 30, wherein measuring the release of IL-2 is determined by ELISA.

### Claim 34 (depends on 27)

The method of claim 27, wherein the material comprises hybridomal clones.

### Claim 35

A fusion protein comprising a single chain variable fragment (scFv) of an anti-human CD3 mAb OKT3 fused to the C-terminal domain (113-220) of mouse CD8α according to SEQ ID NO: 89.

### Claim 36 (depends on 35)

A nucleic acid encoding the fusion protein according to claim 35.

### Claim 37 (depends on 35)

A cell line expressing the fusion protein according to claim 35.

### Claim 38 (depends on 37)

The cell line according to claim 37, wherein the cell line expresses PD-L1 or PD-L2.

### Claim 39 (depends on 37)

The cell line of claim 37, wherein the cell line is a human T cell line.

### Claim 40 (depends on 37)

The cell line of claim 37, wherein the cell line is transfected with a nucleic acid encoding the fusion protein.

### Claim 41 (depends on 35)

A method of screening or selecting for an anti-PD-1 antibody comprising:
(a) providing a material to be assayed, screened or selected against;
(b) screening the material using the fusion protein of claim 35; and
(c) selecting an anti-PD-1 antibody.

### Claim 42 (depends on 41)

The method of claim 41, comprising incubating the material with a cell line expressing the fusion protein.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cell line incubated with the anti-PD-1 antibody is co-cultured with a T cell line expressing PD-1.
